search
Back to results

Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation (CONSTIMOD)

Primary Purpose

Constipation

Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
sacral nerve modulation
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Constipation focused on measuring constipation, sacral nerve modulation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age ≥ 18 years old
  • Constipation defined by at least two of the following criteria :

    • Frequency of 2 stools or less per week
    • Severe outlet constipation, i.e. need to use digital extraction or enemas more than 25% of time
    • Sensation of incomplete evacuation more than 25% of time
  • Refractory constipation since at least 1 year to medical treatment (drug treatment and/or biofeedback) conducted in the centre (failure or intolerance to laxative osmotic treatments, stimulants, and prucalopride) for which surgery is discussed
  • Patients supported in the centre for at least 3 months before inclusion
  • Patients having social security system
  • Patients having read and signed informed consent form

Exclusion Criteria:

  • Constipation secondary to ano-rectal malformation, surgical sequel, colorectal or anal organic lesions, or pelvi-perineal static disorder indicated for surgical treatment
  • Constipation secondary to neurological pathology and/or concomitant treatments intake (opiates, anticholinergic agents)
  • Partial colectomy history
  • Patients in whom implantation of stimulating electrode is impossible due to anatomical reasons (e.g. sacral agenesis)
  • Pregnant female patients or with childbearing potential without adequate contraceptive barrier (oestrogen-progesterone contraceptives or intra-uterine device)
  • Skin disease associated with a risk of infection - in the opinion of the investigator
  • Patient with pacemaker or defibrillator
  • Patient exposed to resonance magnetic imaging
  • Psychiatric disease incompatible with use of the treatment - in the opinion of the investigator
  • Patient misunderstanding oral and written French language
  • Patient participating to another study
  • Patients who don't complete the first diary without missing data (concerning items used to define the primary endpoint)

Sites / Locations

  • Service d' Hépato-gastro-entérologie
  • Service d'hépato-gastroentérologie et oncologie digestive
  • Service d'hépato-gastroentérologie - CHU estaing
  • Service de gastroentérologie - AP HP
  • Service de Chirurgie générale - CHU de Grenoble
  • Service d'exploration fonctionnelle digestive -Hospices Civils de Lyon
  • Service de gastroentérologie - hopital nord -AP-HM
  • : Clinique de chirurgie digestive et endocrinienne. Institut des Maladies de l'Appareil Digestif (IMAD
  • SMAD CHU Pontchaillou -Rennes
  • Service de physiologie digestive, urinaire, respiratoire et sportive - CHU de rouen
  • Service d'hépato-gastroentérologie et explorations fonctionnelles digestives - CHU de Tours

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Arm on-off

Arm off-on

Arm Description

After the definitive implantation, stimulators are placed in position OFF during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks

After the definitive implantation, stimulators are placed in position ON during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks

Outcomes

Primary Outcome Measures

Percentage of patients showing a positive response to sacral nerve stimulation at 2 months
Percentage of patients showing a positive response to sacral nerve stimulation during the period " ON " compared with the period " OFF " based on an objective assessment of the number of feces and their characteristics

Secondary Outcome Measures

Clinical characteristics, manometry data, Wexner score of responders to stimulation during the temporary stimulation test (period before the permanent implantation)
Clinical characteristics, manometry data, Wexner score of responders to short-term stimulation
Efficacy of neuromodulation
Efficacy of neuromodulation (percentage of positive responders) at 1 year
Manometry data, Wexner, QoL and EVA scores, time of colonic transit of responders to prolonged stimulation
To evaluate the investigator opinion about the neuromodulation response, using the patient diary.

Full Information

First Posted
June 11, 2012
Last Updated
July 22, 2015
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT01629303
Brief Title
Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation
Acronym
CONSTIMOD
Official Title
Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
June 2012 (undefined)
Primary Completion Date
November 2013 (Actual)
Study Completion Date
January 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Subjects with refractory chronic constipation are offered two conventional therapeutic strategies: either medical treatment, either surgery (in the case of medication failure). Nevertheless, a procedure less invasive than surgery could be an alternative strategy: the sacral nerve modulation. This procedure consists in stimulating the nerves which control the contractions of the colon and so the defecation phenomenon. Several open trials have suggested that sacral nerve modulation may be effective in reducing constipation and related symptoms. The aim of this randomized clinical trial is to assess the efficacy of the sacral nerve stimulation in patients with constipation.
Detailed Description
The prevalence of constipation is 2-27% in Western countries. For patients failing medical treatment (laxatives, biofeedback), a surgical solution may be considered (subtotal colectomy). But results are variable and it puts them at risk of functional sequelae. Sacral nerve modulation is a minimally invasive procedure compared with the standard surgical support (colectomy) and reversible, which consists in two stages. First, a 3-week temporary stimulation test allows verifying the efficacy of neuromodulation. If the test is positive, the stimulating electrode is definitely implanted. Risks related to the procedure (infection, pain) are much smaller than those associated with a conventional surgical support. Non comparative studies conducted with 19 and 62 patients showed that 40-73% of implanted patients have an improvement of their constipation and could benefit of permanent implantation with good results in medium term. The primary objective of the investigators study is to evaluate the short-term efficacy (percentage of responders at 2 months) of sacral nerve modulation in the treatment of severe chronic constipation. This is a cross-over designed, double-blinded, French multicenter clinical trial, including two periods: 2 months of stimulation ON and 2 months of stimulation OFF. Between these two periods, a 15-days period of "wash-out" will be respected during which all patients will be in OFF mode (4.5 months in total). This period of 4.5 months will be extended by a follow-up period of 7 months during which all patients will be treated (stimulation ON). If this trial showed efficiency of this procedure, patients with severe refractory constipation could benefit of a sacral nerve modulation test before considering a surgical treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
constipation, sacral nerve modulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm on-off
Arm Type
Experimental
Arm Description
After the definitive implantation, stimulators are placed in position OFF during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are switched ON for the second arm during 8 weeks
Arm Title
Arm off-on
Arm Type
Experimental
Arm Description
After the definitive implantation, stimulators are placed in position ON during 8 weeks. Then all the stimulators are switched OFF for 15 days. Finally stimulators are maintained in position OFF during 8 weeks
Intervention Type
Procedure
Intervention Name(s)
sacral nerve modulation
Intervention Description
After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks. Then all the stimulators are switched OFF (both first and second arms) for 15 days. Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks
Primary Outcome Measure Information:
Title
Percentage of patients showing a positive response to sacral nerve stimulation at 2 months
Description
Percentage of patients showing a positive response to sacral nerve stimulation during the period " ON " compared with the period " OFF " based on an objective assessment of the number of feces and their characteristics
Time Frame
2 months of the stimualtion period
Secondary Outcome Measure Information:
Title
Clinical characteristics, manometry data, Wexner score of responders to stimulation during the temporary stimulation test (period before the permanent implantation)
Time Frame
3 weeks between temporary and permanent implantations
Title
Clinical characteristics, manometry data, Wexner score of responders to short-term stimulation
Time Frame
2 months after permanent implantation
Title
Efficacy of neuromodulation
Description
Efficacy of neuromodulation (percentage of positive responders) at 1 year
Time Frame
1 year after permanent implantation
Title
Manometry data, Wexner, QoL and EVA scores, time of colonic transit of responders to prolonged stimulation
Time Frame
1 year after permanent implantation
Title
To evaluate the investigator opinion about the neuromodulation response, using the patient diary.
Time Frame
1 year after permanent implantation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old Constipation defined by at least two of the following criteria : Frequency of 2 stools or less per week Severe outlet constipation, i.e. need to use digital extraction or enemas more than 25% of time Sensation of incomplete evacuation more than 25% of time Refractory constipation since at least 1 year to medical treatment (drug treatment and/or biofeedback) conducted in the centre (failure or intolerance to laxative osmotic treatments, stimulants, and prucalopride) for which surgery is discussed Patients supported in the centre for at least 3 months before inclusion Patients having social security system Patients having read and signed informed consent form Exclusion Criteria: Constipation secondary to ano-rectal malformation, surgical sequel, colorectal or anal organic lesions, or pelvi-perineal static disorder indicated for surgical treatment Constipation secondary to neurological pathology and/or concomitant treatments intake (opiates, anticholinergic agents) Partial colectomy history Patients in whom implantation of stimulating electrode is impossible due to anatomical reasons (e.g. sacral agenesis) Pregnant female patients or with childbearing potential without adequate contraceptive barrier (oestrogen-progesterone contraceptives or intra-uterine device) Skin disease associated with a risk of infection - in the opinion of the investigator Patient with pacemaker or defibrillator Patient exposed to resonance magnetic imaging Psychiatric disease incompatible with use of the treatment - in the opinion of the investigator Patient misunderstanding oral and written French language Patient participating to another study Patients who don't complete the first diary without missing data (concerning items used to define the primary endpoint)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank ZERBIB, Professor
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Genevieve CHENE, Professor
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Study Chair
Facility Information:
Facility Name
Service d' Hépato-gastro-entérologie
City
CHU de Limoges
State/Province
Limoges
ZIP/Postal Code
87000
Country
France
Facility Name
Service d'hépato-gastroentérologie et oncologie digestive
City
Bordeaux
ZIP/Postal Code
33075
Country
France
Facility Name
Service d'hépato-gastroentérologie - CHU estaing
City
Clermont Ferrand
ZIP/Postal Code
63000
Country
France
Facility Name
Service de gastroentérologie - AP HP
City
Colombes
ZIP/Postal Code
92000
Country
France
Facility Name
Service de Chirurgie générale - CHU de Grenoble
City
Grenoble
ZIP/Postal Code
38000
Country
France
Facility Name
Service d'exploration fonctionnelle digestive -Hospices Civils de Lyon
City
Lyon
ZIP/Postal Code
69000
Country
France
Facility Name
Service de gastroentérologie - hopital nord -AP-HM
City
Marseille
ZIP/Postal Code
13000
Country
France
Facility Name
: Clinique de chirurgie digestive et endocrinienne. Institut des Maladies de l'Appareil Digestif (IMAD
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
SMAD CHU Pontchaillou -Rennes
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Name
Service de physiologie digestive, urinaire, respiratoire et sportive - CHU de rouen
City
Rouen
ZIP/Postal Code
76000
Country
France
Facility Name
Service d'hépato-gastroentérologie et explorations fonctionnelles digestives - CHU de Tours
City
Tours
ZIP/Postal Code
37000
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
27779312
Citation
Zerbib F, Siproudhis L, Lehur PA, Germain C, Mion F, Leroi AM, Coffin B, Le Sidaner A, Vitton V, Bouyssou-Cellier C, Chene G; CONSTIMOD study investigators. Randomized clinical trial of sacral nerve stimulation for refractory constipation. Br J Surg. 2017 Feb;104(3):205-213. doi: 10.1002/bjs.10326. Epub 2016 Oct 25.
Results Reference
derived

Learn more about this trial

Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation

We'll reach out to this number within 24 hrs